Situation
A global biopharmaceutical company specializing in rare diseases was exploring expansion into select Asia-Pacific (APAC) markets and needed to determine whether its products could be made accessible to patients in markets with limited public reimbursement and private insurance coverage.
The company needed a clear view of patient affordability, available funding mechanisms, and the broader payer and reimbursement landscape to determine whether a sustainable access pathway could be established.
The challenge was not simply understanding the market but rather determining what access could realistically look like for patients in each country with local realities in mind.
Solution
Axios combined its experience in access strategy with proprietary affordability methodologies to assess the feasibility of sustainable access across priority markets.
- Conducted an ability-to-pay assessment using Axios’ affordability model to understand what patients not covered by public systems or private insurance could realistically contribute toward treatment.
- Mapped public, private, and charitable funding mechanisms available to patients in each market.
- Assessed the payer and reimbursement landscape, including existing pathways and potential barriers to access.
- Compared market-specific findings to identify the factors that would influence the feasibility of different access approaches.
This provided the company with a market-by-market view of the financial realities facing patients and the mechanisms available to bridge identified access gaps.
Results
The assessment provided the company with actionable insights into patients’ ability to pay, funding availability, and reimbursement dynamics across priority APAC markets.
These findings supported the company’s market entry and access strategy, helping inform decisions around pricing feasibility and potential pathways to sustainable patient access.
